Clinical Trials

Status
Published

1445 Results

Open
Accrual
0%
SWOG Clinical Trial Number
S1916

Feasibility of a Digital Medicine Program in Optimizing Opioid Pain Control in Cancer Patients

Status Notes
This is being distributed for IRB review only.
Research Committee(s)
Cancer Care Delivery
Activated
06-11-2019
Open
SWOG Clinical Trial Number
CTSU/NHLBI-MDS

The National Myelodysplastic Syndromes (MDS) Study

Research Committee(s)
Prevention
Leukemia
Activated
06-01-2019
ClinicalTrials.gov Registry Number
NCT02775383
Open
Accrual
1%
SWOG Clinical Trial Number
S1800A

A PHASE II RANDOMIZED STUDY OF RAMUCIRUMAB PLUS MK3475 (PEMBROLIZUMAB) VERSUS STANDARD OF CARE FOR PATIENTS PREVIOUSLY TREATED WITH IMMUNOTHERAPY FOR STAGE IV OR RECURRENT NON-SMALL CELL LUNG CANCER (LUNG-MAP NON-MATCHED SUB-STUDY)

Status Notes
S1800A will open to accrual May 17, 2019, effective 11:00 am PST.

This is a potential FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
Research Committee(s)
Lung Cancer
Activated
05-17-2019
Open
Phase
III
Accrual
0%
SWOG Clinical Trial Number
S1806
Open
SWOG Clinical Trial Number
CTSU/NRG-BR004

A Randomized, Double-Blind, Phase III Trial of Paclitaxel/ Trastuzumab/ Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer

Status Notes
Activated by NRG: 3/12/19.
Activated by SWOG: 4/1/19.
Activated
04-01-2019
ClinicalTrials.gov Registry Number
NCT03199885
Open
Phase
Accrual
1%
SWOG Clinical Trial Number
S1714

A Prospective Observational Cohort Study to Develop a Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer Patients

Status Notes
This study is active as of 3/1/19.
Research Committee(s)
Symptom Control and Quality of Life
Breast Cancer
Lung Cancer
Early Therapeutics & Rare Cancers
Activated
03-01-2019
Open
Phase
SWOG Clinical Trial Number
CTSU/EAE161

Perfusion CT to Predict Progression-free Survival and Response Rate in Bevacizumab and Paclitaxel Treatment of Platinum-Resistant Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Peritoneal Carcinoma

Status Notes
SWOG Activated/Championed CTSU/EAE161, effective March 1, 2019
Research Committee(s)
Early Therapeutics & Rare Cancers
Activated
03-01-2019
ClinicalTrials.gov Registry Number
NCT03412630
Open
Phase
III
Accrual
4%
SWOG Clinical Trial Number
S1600

A Randomized Phase III Double-Blind Clinical Trial Evaluating the Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes

Status Notes
This study is open effective February 21, 2019 at 2:00 p.m. Eastern.
Research Committee(s)
Symptom Control and Quality of Life
Genitourinary Cancer
Activated
02-21-2019
ClinicalTrials.gov Registry Number
NCT03757949
Open
Accrual
0%
SWOG Clinical Trial Number
S1614

Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus (HBV) Infection Receiving Cytotoxic Therapy for Solid Tumors

Status Notes
Active 2/21/19
Research Committee(s)
Symptom Control and Quality of Life
Breast Cancer
Gastrointestinal Cancer
Genitourinary Cancer
Lung Cancer
Melanoma
Activated
02-21-2019
Open
SWOG Clinical Trial Number
LUNGMAP

A MASTER PROTOCOL TO EVALUATE BIOMARKER-DRIVEN THERAPIES AND IMMUNOTHERAPIES IN PREVIOUSLY-TREATED NON-SMALL CELL LUNG CANCER (Lung-MAP Screening Study)

Status Notes
LUNGMAP will open to accrual January 28, 2019, effective 2:00 pm PST.

This is a potential FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
Research Committee(s)
Lung Cancer
Activated
01-28-2019
ClinicalTrials.gov Registry Number
NCT03851445
Open
SWOG Clinical Trial Number
S1900BDSS

S1900 Biomarker-Driven Sub-Study Version Control Protocol (S1900BDSS VCP)

Status Notes
The LUNGMAP S1900 Biomarker-Driven Sub-Study Version Control Protocol (S1900BDSS) is active effective 1/28/19.

The intent of the S1900BDSS is to allow an individual sub-study to be revised independently of the other sub-studies. The S1900BDSS keeps track of revisions made to various S1900 biomarker-driven sub-studies of LUNGMAP and their component documents over the course of the overarching Lung-MAP study, and lists the version date of each revision.

Sites may use this document to verify the most current version of a LUNGMAP S1900 biomarker-driven sub-study, and may also reference this document for an overview of S1900 sub-study revisions.
Research Committee(s)
Lung Cancer
Activated
01-28-2019
Open
Accrual
4%
SWOG Clinical Trial Number
S1801

A Phase II Randomized Study of Adjuvant versus Neoadjuvant Pembrolizumab for Clinically Detectable Stage III-IV High-risk Melanoma.

Status Notes
Activation Effective 12/06/2018.
Research Committee(s)
Melanoma
Activated
12-06-2018
Open
Accrual
14%
SWOG Clinical Trial Number
S1815

A phase III randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers

Status Notes
Activation effective Monday, December 3, 2018.
Research Committee(s)
Gastrointestinal Cancer
Activated
12-03-2018
Open
Phase
Accrual
5%
SWOG Clinical Trial Number
S1802

Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer

Status Notes
Activated 9/17/18.
Research Committee(s)
Genitourinary Cancer
Other
Symptom Control and Quality of Life
Activated
09-17-2018
Open
Accrual
3%
SWOG Clinical Trial Number
S1706

A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer

Status Notes
Activation, Effective 9/12/2018, 2:00 pm CT
Research Committee(s)
Breast Cancer
Activated
09-12-2018
ClinicalTrials.gov Registry Number
NCT03598257
Open
Phase
II
Accrual
2%
SWOG Clinical Trial Number
S1701

A Randomized Phase II trial of Carboplatin-Paclitaxel with or without Ramucirumab in Patients with Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma

Status Notes
This study is open to accrual effective 8/9/18.
Research Committee(s)
Lung Cancer
Activated
08-09-2018
ClinicalTrials.gov Registry Number
03694002
Open
Phase
II
Accrual
8%
SWOG Clinical Trial Number
S1712
Open
Accrual
72%
SWOG Clinical Trial Number
S1702

A Phase II Study of Isatuximab (SAR650984) for Patients with Previously Treated AL Amyloidosis

Status Notes
This study is active for patient participation effective 3/8/18 at 2:00 p.m. Eastern.
Research Committee(s)
Myeloma
Activated
03-08-2018